Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

Housing Shows Signs of Perking Up

Among the encouraging signs: Applications for home loans recently hit a nine-year peak and new home sales in March posted a 16-month high.

A Tough Week for Biotech, the Candidates' Whipping Boy Again

Talk among a mammoth field of presidential candidates about drug price controls and an expansion of Medicare isn't helping biotech and health care stocks.

These 2 Biotech Stocks Are No Longer 'Off the Radar'

Few parts of the market have more volatility than the small caps in this sector.

Discovery Financial Is a Solid, Low-Beta Value Play

A look at the financials as earnings season kicks into high gear.

These 3 Biotech Stocks Are Moving Closer to Profitability

Here are updates on small biotech/biopharma names I have profiled before.

You Don't Have to Swing for the Fences With Every Investment in Small Caps

The way I do that is by using buy-write option strategies.

Stepping Carefully Into the Second Quarter

The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.

Construction Stocks Positioned to Claw Back 2018 Declines

Construction spending hasn't sent ambivalent signals in 2019.

3 Promising Small Biotech Stocks to Watch

I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight